395 related articles for article (PubMed ID: 20335016)
1. Interleukin-6 in bone metastasis and cancer progression.
Ara T; Declerck YA
Eur J Cancer; 2010 May; 46(7):1223-31. PubMed ID: 20335016
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells.
Ara T; Song L; Shimada H; Keshelava N; Russell HV; Metelitsa LS; Groshen SG; Seeger RC; DeClerck YA
Cancer Res; 2009 Jan; 69(1):329-37. PubMed ID: 19118018
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-6 receptor inhibitor suppresses bone metastases in a breast cancer cell line.
Wakabayashi H; Hamaguchi T; Nagao N; Kato S; Iino T; Nakamura T; Sudo A
Breast Cancer; 2018 Sep; 25(5):566-574. PubMed ID: 29557068
[TBL] [Abstract][Full Text] [Related]
4. Combination of interleukin-6 and soluble interleukin-6 receptors induces differentiation and activation of JAK-STAT and MAP kinase pathways in MG-63 human osteoblastic cells.
Nishimura R; Moriyama K; Yasukawa K; Mundy GR; Yoneda T
J Bone Miner Res; 1998 May; 13(5):777-85. PubMed ID: 9610741
[TBL] [Abstract][Full Text] [Related]
5. In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway.
Chatterjee M; Hönemann D; Lentzsch S; Bommert K; Sers C; Herrmann P; Mathas S; Dörken B; Bargou RC
Blood; 2002 Nov; 100(9):3311-8. PubMed ID: 12384432
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-6: A Masterplayer in the Cytokine Network.
Uciechowski P; Dempke WCM
Oncology; 2020; 98(3):131-137. PubMed ID: 31958792
[TBL] [Abstract][Full Text] [Related]
7. Plumbagin inhibits breast tumor bone metastasis and osteolysis by modulating the tumor-bone microenvironment.
Li Z; Xiao J; Wu X; Li W; Yang Z; Xie J; Xu L; Cai X; Lin Z; Guo W; Luo J; Liu M
Curr Mol Med; 2012 Sep; 12(8):967-81. PubMed ID: 22574935
[TBL] [Abstract][Full Text] [Related]
8. Role of interleukin 6 (IL-6)/IL-6R-induced signal tranducers and activators of transcription and mitogen-activated protein kinase/extracellular.
Legendre F; Bogdanowicz P; Boumediene K; Pujol JP
J Rheumatol; 2005 Jul; 32(7):1307-16. PubMed ID: 15996070
[TBL] [Abstract][Full Text] [Related]
9. IL-6 and soluble IL-6 receptor stimulate the production of MMPs and their inhibitors via JAK-STAT and ERK-MAPK signalling in human chondrocytes.
Aida Y; Honda K; Tanigawa S; Nakayama G; Matsumura H; Suzuki N; Shimizu O; Takeichi O; Makimura M; Maeno M
Cell Biol Int; 2012 Apr; 36(4):367-76. PubMed ID: 22087578
[TBL] [Abstract][Full Text] [Related]
10. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17.
Hashizume M; Hayakawa N; Mihara M
Rheumatology (Oxford); 2008 Nov; 47(11):1635-40. PubMed ID: 18786965
[TBL] [Abstract][Full Text] [Related]
11. Inflammation and prostate cancer: the role of interleukin 6 (IL-6).
Nguyen DP; Li J; Tewari AK
BJU Int; 2014 Jun; 113(6):986-92. PubMed ID: 24053309
[TBL] [Abstract][Full Text] [Related]
12. JAK/STAT but not ERK1/ERK2 pathway mediates interleukin (IL)-6/soluble IL-6R down-regulation of Type II collagen, aggrecan core, and link protein transcription in articular chondrocytes. Association with a down-regulation of SOX9 expression.
Legendre F; Dudhia J; Pujol JP; Bogdanowicz P
J Biol Chem; 2003 Jan; 278(5):2903-12. PubMed ID: 12419823
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas.
Lee TL; Yeh J; Van Waes C; Chen Z
Mol Cancer Ther; 2006 Jan; 5(1):8-19. PubMed ID: 16432158
[TBL] [Abstract][Full Text] [Related]
14. IL-6/IL-6 receptor system and its role in physiological and pathological conditions.
Mihara M; Hashizume M; Yoshida H; Suzuki M; Shiina M
Clin Sci (Lond); 2012 Feb; 122(4):143-59. PubMed ID: 22029668
[TBL] [Abstract][Full Text] [Related]
15. Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells.
Badache A; Hynes NE
Cancer Res; 2001 Jan; 61(1):383-91. PubMed ID: 11196191
[TBL] [Abstract][Full Text] [Related]
16. Direct crosstalk between cancer and osteoblast lineage cells fuels metastatic growth in bone via auto-amplification of IL-6 and RANKL signaling pathways.
Zheng Y; Chow SO; Boernert K; Basel D; Mikuscheva A; Kim S; Fong-Yee C; Trivedi T; Buttgereit F; Sutherland RL; Dunstan CR; Zhou H; Seibel MJ
J Bone Miner Res; 2014 Sep; 29(9):1938-49. PubMed ID: 24676805
[TBL] [Abstract][Full Text] [Related]
17. Gp130 activation by soluble interleukin-6 receptor/interleukin-6 enhances osteoblastic differentiation of human bone marrow-derived mesenchymal stem cells.
Erices A; Conget P; Rojas C; Minguell JJ
Exp Cell Res; 2002 Oct; 280(1):24-32. PubMed ID: 12372336
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies.
Tawara K; Oxford JT; Jorcyk CL
Cancer Manag Res; 2011; 3():177-89. PubMed ID: 21625400
[TBL] [Abstract][Full Text] [Related]
19. Higher proliferation of peritumoral endothelial cells to IL-6/sIL-6R than tumoral endothelial cells in hepatocellular carcinoma.
Zhuang PY; Wang JD; Tang ZH; Zhou XP; Quan ZW; Liu YB; Shen J
BMC Cancer; 2015 Nov; 15():830. PubMed ID: 26525581
[TBL] [Abstract][Full Text] [Related]
20. Secretion of interleukin-6 by bone marrow mesenchymal stem cells promotes metastasis in hepatocellular carcinoma.
Mi F; Gong L
Biosci Rep; 2017 Aug; 37(4):. PubMed ID: 28659496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
